Feasibility of venous thromboembolism prophylaxis during inflammatory bowel disease flares in the outpatient setting: A decision analysis

Inflammatory Bowel Diseases

Volumn 19, Issue 10, 2013, Pages 2182-2189

  Nguyen, Geoffrey C ^a,b,c,d,e   Sharma, Suraj ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Anticoagulation; Cost effectiveness; Crohn's disease; Inflammatory bowel disease; Ulcerative colitis; Venous thromboembolism

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULATION; ARTICLE; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DISEASE EXACERBATION; ENTERITIS; OUTPATIENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; SENSITIVITY ANALYSIS; ULCERATIVE COLITIS; VENOUS THROMBOEMBOLISM;

ADULT; ANTICOAGULANTS; COLITIS, ULCERATIVE; COST-BENEFIT ANALYSIS; CROHN DISEASE; DECISION SUPPORT TECHNIQUES; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OUTPATIENTS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; QUALITY-ADJUSTED LIFE YEARS; VENOUS THROMBOEMBOLISM;

EID: 84884543392     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31829c01ef     Document Type: Article

References (36)

1. Bernstein CN, Blanchard JF, Houston DS, et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost. 2001;85:430-434.
2. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375:657-663.
3. Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103:2272-2280.
4. Bitton A, Buie D, Enns R, et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol. 2012;107:179-194.
5. D'Haens G, Baert F, van AG, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660-667.
6. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571-607.
7. Travis SP, Stange EF, Lemann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis. 2008;2:24-62.
8. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-523.
9. Ra G, Thanabalan R, Ratneswaran S, et al. Predictors and safety of venous thromboembolism prophylaxis among hospitalized inflammatory bowel disease patients. J Crohns Colitis. [published online ahead of print March 25, 2013]. doi: 10.1016/j.crohns.2013.03.002.
10. Papay P, Miehsler W, Tilg H, et al. Clinical presentation of venous thromboembolism in inflammatory bowel disease. J Crohns Colitis. [published online ahead of print November 2, 2012]. doi: 10.1016/j.crohns.2012.10.008.
11. Arias E. United States life tables, 2007. Natl Vital Stat Rep. 2011;59:1-61.
12. Dentali F, Douketis JD, Gianni M, et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med. 2007;146:278-288.
13. Novacek G, Weltermann A, Sobala A, et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology. 2010;139:779-787, 787.
14. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e419S-e494S.
15. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901-907.
16. Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med. 1997; 336:393-398.
17. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for longterm prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631-639.
18. Shen J, Ran ZH, Tong JL, et al. Meta-analysis: the utility and safety of heparin in the treatment of active ulcerative colitis. Aliment Pharmacol Ther. 2007;26:653-663.
19. Carrier M, Le GG, Wells PS, et al. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med. 2010;152: 578-589.
20. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1-7.
21. Saini SD, Waljee AK, Higgins PD. Cost utility of inflammation-targeted therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2012;10:1143-1151.
22. Waljee AK, Higgins PD, Waljee JF, et al. Perceived and actual quality of life with ulcerative colitis: a comparison of medically and surgically treated patients. Am J Gastroenterol. 2011;106:794-799.
23. Gregor JC, McDonald JW, Klar N, et al. An evaluation of utility measurement in Crohn's disease. Inflamm Bowel Dis. 1997;3:265-276.
24. Pishko AM, Smith KJ, Ragni MV. Anticoagulation in ambulatory cancer patients with no indication for prophylactic or therapeutic anticoagulation: a cost-effectiveness analysis from a U.S. perspective. Thromb Haemost. 2012;108:303-310.
25. Locadia M, Bossuyt PM, Stalmeier PF, et al. Treatment of venous thromboembolism with vitamin K antagonists: patients' health state valuations and treatment preferences. Thromb Haemost. 2004;92:1336-1341.
26. U.S. Bureau of Labor Statistics. Available at: http://www.bls.gov/data/. Accessed November 19, 2012.
27. Red Book Online. Available at: https://www.thomsonhc.com/hcs/librarian/ PFDefaultActionId/pf.LoginAction/ssl/true. Accessed November 19, 2012.
28. American Medical Association CodeManager Online. Available at: https://ocm.ama-assn.org/OCM/CPTRelativeValueSearch.do?submitbutton=accept. Accessed November 19, 2012.
29. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907-1913.
30. Lee S, Mullin R, Blazawski J, et al. Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. PLoS One. 2012;7:e47473.
31. Neumann PJ, Sandberg EA, Bell CM, et al. Are pharmaceuticals costeffective? A review of the evidence. Health Aff (Millwood). 2000;19:92-109.
32. Braithwaite RS, Meltzer DO, King JT Jr, et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46:349-356.
33. van AG, Dignass A, Reinisch W, et al. The second European evidencebased consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis. 2010;4:63-101.
34. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(suppl 5):V1-V16.
35. Vinik AI, Zhang Q. Adding insulin glargine versus rosiglitazone: healthrelated quality-of-life impact in type 2 diabetes. Diabetes Care. 2007;30: 795-800.
36. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e195S-e226S.